Bispecific antibodies (bsAbs) enable novel mechanisms of action and/or therapeutic
applications that cannot be achieved using conventional IgG-based antibodies …

Antimicrobial resistance (AMR) is a quickly advancing threat for human health worldwide
and almost 5 million deaths are already attributable to this phenomenon every year. Since …

Abstract Toll‐like receptor 7/8 agonists, such as imidazoquinolines (IMDQs), are promising
for the de novo priming of antitumor immunity. However, their systemic administration is …

Since the approval of the CD20‐targeting monoclonal antibody (mAb) rituximab for the
treatment of lymphoma in 1997, mAb therapy has significantly transformed cancer treatment …

Tumor-associated antigens (TAAs) are not exclusively expressed in cancer cells, inevitably
causing the “on target, off tumor” effect of molecular recognition tools. To achieve precise …

Immunoglobulin G (IgG) antibodies are a critical component of the adaptive immune system,
binding to and neutralizing pathogens and other foreign substances. Recent advances in …

Advances in antibody engineering are being directed at the development of next generation
immunotherapeutics with improved potency. Hexamerisation of IgG is a normal …

The greatest challenge in cancer therapy is to eradicate cancer cells with minimal damage
to normal cells. Targeted therapy has been developed to meet that challenge, showing a …

Multiple receptor analysis-based DNA molecular computation has been developed to
mitigate the off-target effect caused by nonspecific expression of cell membrane receptors …

Tumor necrosis factor receptors (TNFRs) are promising targets for cancer therapy. However,
activating their downstream signaling requires cross‐linking of TNFRs. Herein, to devise …